Biology subjects

Hilton, I. B.

Publications and source records attributed to Hilton, I. B..

5 recordsLinked to original sources

bioRxiv2026

Design of synthetic activators for programmable gene expression

Transcription factors control gene expression by recruiting transcriptional coactivators through intrinsically disordered transcriptional activation domains (TADs), whose weak and promiscuous interactions make it difficult to establish quantitative relationships between coactivator recruitment and transcriptional output, and to precisely modulate gene expression. To overcome this limitation, we set out to design coactivator-recruiting proteins using AlphaFold3-predicted TAD-coactivator interactions as a guide. We developed a high-throughput functional screening platform in mammalian cells and identified over 300 well folded nanomolar affinity binders to the transcription coactivators Mediator (multiple subunits), BRD4, NCOA, and p300; targeted interface mutations enabled systematic tuning of their binding affinities. Using a panel of p300 binders spanning nanomolar to micromolar affinities, we found an ultrasensitive relationship between coactivator-binding affinity and transcriptional output, with a sharp transcriptional activation threshold at ~500 nM. Incorporating p300 binder designs into CRISPRa yielded compact synthetic effectors that drove stronger activation than VPR across multiple genomic loci with minimal detectable cytotoxicity. Combining p300- and Mediator-specific binders further enhanced transcription, revealing functional synergy between these coactivators. Together, our work establishes a quantitative framework linking coactivator-binding affinity to transcriptional output and provides compact synthetic effectors for programmable gene activation.

synthetic biology↗

bioRxiv2025

Robust fluorescent labeling and tracking of endogenous non-repetitive genomic loci

The spatial organization and dynamics of a genome are central to gene regulation. While a comprehensive understanding of chromatin organization in the human nucleus has been achieved using fixed-cell methods, measuring the dynamics of specific genomic regions over extended periods in individual living cells remains challenging. Here, we present a robust and fully genetically encoded system for fluorescent labeling and long-term tracking of any accessible non-repetitive genomic locus in live human cells using fluorogenic and replenishable nanobody array fusions of the Staphylococcus aureus dCas9, and compact polycistronic single guide (sg)RNAs. First, we characterize the selectivity and photostability of our probes, enabling genome-wide visualization of chromatin dynamics at locally repetitive elements. Next, through multiplexed expression of 8-10 sgRNAs from polycistronic cassettes, we demonstrate efficient and sustained labeling of non-repetitive loci, enabling high-fidelity tracking of gene-proximal regions at exceptional spatial and temporal resolution. Finally, by correlating chromatin mobility with transcriptional activity at multiple genes, we find that local chromatin dynamics at 20 Hz are gene-specific and not necessarily dependent on transcription. Our approach is versatile, minimally invasive, and scalable, enabling multiplexed imaging of regulatory element dynamics involved in gene control, with broad applicability across diverse biological systems and disease contexts.

biophysics↗

bioRxiv2024

Tailoring a CRISPR/Cas-based Epigenome Editor for Programmable Chromatin Acylation and Decreased Cytotoxicity

CRISPR-based epi-editors can robustly modulate cellular transcription and chromatin structure, but off-target activity and cytotoxicity limit their utility. Here, we engineer the acyl-CoA binding pocket of the human p300 histone acyltransferase to reduce its cytotoxicity and tune its acylation profile when fused to dCas9. We discover a single amino acid substitution (I1417N) that decreases cytotoxicity related to exogenous p300 overexpression yet preserves dCas9-p300 mediated histone acetylation and gene activation. We find that dCas9-p300 I1417N is less perturbative to the transcriptome and proteome of human cells, and that this behavior is driven by favorable stability kinetics. We also develop a crotonylation-biased dCas-p300 variant (I1395G) that selectively deposits histone crotonylation and activates transcription from endogenous promoters at levels comparable to wild-type p300. The p300 variants generated here enhance epi-editing capabilities and demonstrate that engineering of catalytic domains can be a powerful strategy for tailoring enzymatic activities and mitigating effector-driven toxicity in epi-editing.

synthetic biology↗

bioRxiv2024

Persistent tailoring of MSC activation through genetic priming

Mesenchymal stem/stromal cells (MSCs) are an attractive platform for cell therapy due to their safety profile and unique ability to secrete broad arrays of immunomodulatory and regenerative molecules. Yet, MSCs are well known to require preconditioning or priming to boost their therapeutic efficacy. Current priming methods offer limited control over MSC activation, yield transient effects, and often induce expression of pro-inflammatory effectors that can potentiate immunogenicity. Here, we describe a genetic priming method that can both selectively and sustainably boost MSC potency via the controlled expression of the inflammatory-stimulus-responsive transcription factor IRF1 (interferon response factor 1). MSCs engineered to hyper-express IRF1 recapitulate many core responses that are accessed by biochemical priming using the proinflammatory cytokine interferon-{gamma} (IFN{gamma}). This includes the upregulation of anti-inflammatory effector molecules and the potentiation of MSC capacities to suppress T cell activation. However, we show that IRF1-mediated genetic priming is much more persistent than biochemical priming and can circumvent IFN{gamma}-dependent expression of immunogenic MHC class II molecules. Together, the ability to sustainably activate and selectively tailor MSC priming responses creates the possibility of programming MSC activation more comprehensively for therapeutic applications. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=158 SRC="FIGDIR/small/578489v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@8be46aorg.highwire.dtl.DTLVardef@40fcdeorg.highwire.dtl.DTLVardef@995a21org.highwire.dtl.DTLVardef@1ec53d0_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗

bioRxiv2022

Compact engineered human transactivation modules enable potent and versatile synthetic transcriptional control

Engineered transactivation domains (TADs) combined with programmable DNA binding platforms have revolutionized synthetic transcriptional control. Despite recent progress in programmable CRISPR/Cas-based transactivation (CRISPRa) technologies, the TADs used in these systems often contain poorly tolerated elements and/or are prohibitively large for many applications. Here we defined and optimized minimal TADs built from human mechanosensitive transcription factors (MTFs). We used these components to construct potent and compact multipartite transactivation modules (MSN, NMS, and eN3x9) and to build the CRISPR-dCas9 recruited enhanced activation module (CRISPR-DREAM) platform. We found that CRISPR-DREAM was specific, robust across mammalian cell types, and efficiently stimulated transcription from diverse regulatory loci. We also showed that MSN and NMS were portable across Type I, II, and V CRISPR systems, TALEs, and ZF proteins. Further, as proofs of concepts, we used dCas9-NMS to efficiently reprogram human fibroblasts into iPSCs and demonstrated that MTF TADs are efficacious and well tolerated in therapeutically important primary human cell types. Finally, we leveraged the compact and potent features of these engineered TADs to build new dual and all-in-one CRISPRa AAV systems. Altogether, these compact human TADs, fusion modules, and new delivery architectures should be valuable for synthetic transcriptional control in biomedical applications.

bioengineering↗